Peptides for Immune Support

Immune peptide therapy sits in an interesting space between immunostimulants (which broadly activate the immune system) and immunosuppressants (which broadly suppress it). The peptides in this category offer more targeted modulation, either enhancing specific immune cell populations or shifting the balance between inflammatory and regulatory responses. Thymosin alpha-1 is the flagship immune peptide. Originally isolated from thymus tissue by Goldstein in the 1970s, it's now manufactured synthetically and has been used in millions of patients worldwide. It received regulatory approval in over 35 countries (under the brand name Zadaxin) for hepatitis B, hepatitis C, and as an immune adjuvant, though the FDA never approved it in the US. Its mechanism centers on dendritic cell activation, Th1 response enhancement, and natural killer cell stimulation. LL-37 (the only human cathelicidin antimicrobial peptide) provides direct pathogen killing by disrupting microbial membranes. But its immune effects go beyond simple antimicrobial activity: it also acts as an immunomodulator, recruiting neutrophils and macrophages to infection sites, promoting wound healing, and modulating cytokine production. Some researchers have investigated its potential in conditions ranging from chronic infections to wound healing. Thymulin is the zinc-dependent thymic peptide that guides T-cell development. Its levels decline sharply with age as the thymus involutes, making it a candidate for immune restoration in older adults. Thymulin requires adequate zinc status for biological activity, which has implications for supplementation protocols. The practical approach to immune peptide therapy depends on the clinical goal. For immune enhancement in immunocompromised patients or during chronic infections, thymosin alpha-1 has the strongest evidence base. For antimicrobial support or recurrent infections, LL-37 offers direct pathogen defense. For age-related immune decline, thymulin combined with zinc optimization addresses the thymic component. Costs range from $100-400/month depending on peptide selection. Thymosin alpha-1 is the most expensive due to its established clinical use and larger dosing requirements. LL-37 and selank are in the mid-range.